4.7 Article

Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Prognostic significance of IKZF1 deletions and IKZF1plus profile in children with B-cell precursor acute lymphoblastic leukemia treated according to the ALL-IC BFM 2009 protocol

Marcin Braun et al.

Summary: The presence of minimal residual disease (MRD) and specific molecular abnormalities, such as IKZF1 gene aberrations, are strong predictors of outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). A recently-defined IKZF1-plus microdeletion profile can provide additional predictive value for treatment outcome in childhood BCP-ALL and contribute to more efficient patient stratification.

HEMATOLOGICAL ONCOLOGY (2022)

Review Biochemistry & Molecular Biology

Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children

Monika Lejman et al.

Summary: Acute lymphoblastic leukemia is a heterogeneous disease characterized by abnormal proliferation of immature lymphoid cells. The study of genomic alterations has identified new subtypes of this disease and these genetic abnormalities play important roles in early disease detection, risk stratification, and treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Hematology

Novel strategies in the treatment of acute lymphoblastic leukaemia

Anjali S Advani

Lancet Haematology (2022)

Article Biochemistry & Molecular Biology

Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia

Clara Vicente-Garces et al.

Summary: The development of a targeted NGS panel has been validated for use in pediatric acute leukemia diagnosis, prognosis, and treatment, showing high sensitivity and specificity for detecting genetic variants and fusion genes associated with childhood cancer.

FRONTIERS IN MOLECULAR BIOSCIENCES (2022)

Article Hematology

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber et al.

Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.
Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Rita Alaggio et al.

Summary: This article provides an overview of the upcoming 5th edition of the World Health Organization classification of lymphoid tumors, highlighting changes from the previous edition such as reorganization of entities, modification of nomenclature, revision of diagnostic criteria, deletion of entities, introduction of new entities, and inclusion of tumor-like lesions.

LEUKEMIA (2022)

Review Pediatrics

Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era

Mengxuan Shang et al.

Summary: With the development of medical technology, the prognosis for pediatric R/R B-ALL patients has significantly improved. Individualized treatment can now be achieved using emerging technologies, and more effective immunotherapies and molecular targeted drugs have been developed.

FRONTIERS IN PEDIATRICS (2022)

Article Oncology

Impact of IKZF1 Deletions in the Prognosis of Childhood Acute Lymphoblastic Leukemia in Argentina

Maria Sara Felice et al.

Summary: Deletions in the IKZF1 gene have been associated with poor prognosis in ALL. The co-occurrence of these deletions with deletions in other genes appears to better define prognosis. The study shows that the status of IKZF1 can influence the survival of pediatric ALL patients, especially in those with intermediate risk.

CANCERS (2022)

Article Genetics & Heredity

The genomic landscape of pediatric acute lymphoblastic leukemia

Samuel W. Brady et al.

Summary: A comprehensive analysis of genomic and transcriptomic data from 2,754 childhood acute lymphoblastic leukemias revealed 376 putative driver genes, as well as associations between disease subtypes and prognosis.

NATURE GENETICS (2022)

Review Biotechnology & Applied Microbiology

A Comprehensive Review of Performance of Next-Generation Sequencing Platforms

Muhammad Tariq Pervez et al.

Summary: This study investigated various sequencing instruments and found that Nanopore PromethION is the fastest sequencing approach, with BGI and Nanopore outperforming the popular Illumina sequencing company. In terms of quality, Ion Torrent NGS instruments ranked first, Illumina ranked second, and BGI DNB ranked third. The study also highlighted the need to develop memory- and time-saving algorithms and databases to analyze data from third- and fourth-generation sequencing methods.

BIOMED RESEARCH INTERNATIONAL (2022)

Article Hematology

Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical Setting

Tatjana Pandzic et al.

Summary: This article discusses the clinical significance of small TP53 clones detected in chronic lymphocytic leukemia using next generation sequencing (NGS), and proposes a robust diagnostic algorithm for safely detecting and reporting TP53 variants with variant allele frequency (VAF) as low as 5%.

HEMASPHERE (2022)

Review Oncology

Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia

Marta Malczewska et al.

Summary: Acute lymphoblastic leukemia is the most common blood cancer in pediatric patients. Despite significant progress in treatment, some patients cannot be saved. Conventional methods of treatment carry high toxicities, reducing effectiveness and sometimes leading to death. Novel treatments, including targeted treatment, CAR-T-cell therapy, and immunotherapy, are being explored.

CANCERS (2022)

Review Biochemistry & Molecular Biology

The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia

Marta Weronika Lato et al.

Summary: Childhood acute lymphoblastic leukemia is a genetically heterogeneous cancer with T-ALL accounting for a portion. Despite the lack of genetic prognostic markers, high-throughput molecular methods have improved subgroup identification, treatment selection, and disease outcomes. Novel therapies targeting molecular aberrations offer promise in improving remission rates and preventing relapse, with nelarabine-based regimens remaining the standard for treating relapse of T-ALL.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Review Medical Laboratory Technology

Integrated diagnostics: the future of laboratory medicine?

Giuseppe Lippi et al.

BIOCHEMIA MEDICA (2020)

Correction Biochemistry & Molecular Biology

Oviz-Bio: a web-based platform for interactive cancer genomics data visualization (vol 48, pg W415, 2020)

Wenlong Jia et al.

NUCLEIC ACIDS RESEARCH (2020)

Review Hematology

Pediatric acute lymphoblastic leukemia

Hiroto Inaba et al.

HAEMATOLOGICA (2020)

Article Biochemistry & Molecular Biology

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia

Dan Li et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Article Genetics & Heredity

Targeted next generation sequencing as a tool for precision medicine

Markus Gulilat et al.

BMC MEDICAL GENOMICS (2019)

Review Medicine, General & Internal

Acute Lymphoblastic Leukemia in Children

Stephen P. Hunger et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Medicine, General & Internal

Germline Mutations in Predisposition Genes in Pediatric Cancer

Jinghui Zhang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Biochemistry & Molecular Biology

Circos: An information aesthetic for comparative genomics

Martin Krzywinski et al.

GENOME RESEARCH (2009)